Executive Summary
The August 5, 2026 filings reveal a highly active M&A landscape dominated by SPAC activity and strategic asset transactions. Key themes include a wave of SPAC IPOs (East West Ave, BOA Acquisition Corp II) raising $225M combined, and de-SPAC progress with McKinley Acquisition Corp announcing a $638M merger with Space-Eyes.
Notable strategic M&A includes CoreCivic's $734M sale of two detention facilities to the DHS, and Palomino Laboratories' acquisition of Vega Links to expand into AI interconnects. Eton Pharmaceuticals licensed a promising late-stage dermatology product, while Medalist Diversified REIT executed a portfolio transformation through $76.6M in property dispositions. However, several SPACs (Charlton Aria, New America Acquisition I) show signs of distress with extended deadlines and director departures. NCR Voyix reported mixed Q2 results with revenue declining 21% YoY but recurring revenue growing, while maintaining full-year guidance. The overall sentiment is cautiously positive for active deal-making but with significant execution risks in the SPAC sector.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K · Schedule 13D
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from August 04, 2026.
Investment Signals (12)
- McKinley Acquisition Corp (MKLY) ↓ (BULLISH)▲
Definitive $638M merger with Space-Eyes, a high-growth AI geospatial intelligence company, with $75M PIPE financing and strategic adviser Eric Trump. The deal provides a clear path to public markets for a defense-tech firm.
- CoreCivic, Inc. (CXW) ↓ (BULLISH)▲
Completed $734M sale of two detention facilities to DHS, generating $522.5M net proceeds while retaining operating contracts through 2027-2031. This unlocks significant value while maintaining recurring revenue streams.
- Eton Pharmaceuticals (ETON) (BULLISH)▲
Licensed ASN-001 (timolol topical gel) with patent protection through 2044, targeting 20,000-30,000 annual patients. Phase II/III data showed 56% efficacy vs 15% placebo, with NDA submission expected in 2H 2027.
- Palomino Laboratories ↓ (BULLISH)▲
Closed acquisition of Vega Links, expanding addressable market 10x to $60B+ in AI interconnects. Appointed experienced CTO and CPO, adding strategic advisors. Positioned to capitalize on AI infrastructure buildout.
- NCR Voyix Corp (VYX) ↓ (BULLISH)▲
Q2 revenue of $523M declined 21% YoY but software/services grew to $497M with recurring revenue of $435M. Adjusted EBITDA improved to $98M. Maintained full-year outlook of $2,188M-$2,303M, suggesting stabilization.
- Medalist Diversified REIT (MDRR) (BULLISH)▲
Completed $76.6M in property dispositions, reducing debt by 52.3% and increasing equity 11.3%. Strategic pivot to a leaner, more liquid balance sheet.
- East West Ave Acquisition Corp ↓ (NEUTRAL)▲
Completed $100M IPO at $10/unit, providing dry powder for future M&A. Units trade on Nasdaq under EWAVU.
- BOA Acquisition Corp II ↓ (NEUTRAL)▲
Priced $125M IPO targeting real estate and infrastructure assets in energy, telecom, and transportation sectors. Provides a vehicle for sector-specific M&A.
- Charlton Aria Acquisition Corp ↓ (BEARISH)▲
Deposited second $850K extension fee to push deadline to October 25, 2026, totaling $1.7M in sponsor deposits. No target identified yet, indicating potential distress.
- New America Acquisition I Corp ↓ (BEARISH)▲
Director and officer departures without disclosed merger target suggest possible deal failure or restructuring. No financial details provided.
- Inflection Point Acquisition Corp III ↓ (BEARISH)▲
Shareholder approval obtained for merger but no target, size, or terms disclosed. Complete lack of transparency raises red flags.
- Legato Merger Corp IV (LEGO) ↓ (BEARISH)▲
CIO Ehsan Ehsani resigned effective July 31, 2026, with no replacement named. Key personnel departure during deal-making phase is concerning.
Risk Flags (10)
- Charlton Aria Acquisition Corp/Extension Risk↓ [HIGH RISK]▼
Second three-month extension used, exhausting all permitted extensions. If no deal by October 25, 2026, the SPAC must liquidate. Sponsor has already invested $1.7M with no target identified.
- ▼
Filing lacks any merger target, deal size, or valuation. Director/officer departures without explanation suggest internal turmoil or deal collapse.
- ▼
Shareholder approval obtained but no target company, financial terms, or redemption data disclosed. Investors have no basis to evaluate the merger.
- Catalyst Acquisition Corp/No Deal Details↓ [HIGH RISK]▼
SC 13D filing contains zero specifics on deal structure, parties, or valuation. Complete lack of transparency prevents any risk assessment.
- NCR Voyix Corp/Revenue Decline↓ [MEDIUM RISK]▼
Q2 revenue down 21% YoY to $523M due to Hardware Business Transition. Net loss from continuing operations was $1M vs $0 last year. Diluted EPS remains negative at $(0.03).
- Medalist Diversified REIT/Asset Base Shrinkage↓ [MEDIUM RISK]▼
Pro forma total assets declined 19.4% from $68.9M to $55.6M after dispositions. Revenue will drop significantly as income-generating assets are sold.
- CoreCivic/Contract Termination Risk↓ [MEDIUM RISK]▼
ICE retains the right to terminate management contracts for non-appropriation or convenience. Contracts expire in 2027 and 2031, creating long-term revenue uncertainty.
- Eton Pharmaceuticals/Regulatory Risk↓ [MEDIUM RISK]▼
ASN-001 is still in development with no guaranteed FDA approval. Bioavailability bridging study required before NDA submission in 2H 2027. Off-label competition and regulatory hurdles remain.
- AmperCap Acquisition Co/Materiality Risk↓ [LOW RISK]▼
Filing only covers administrative fee payment schedule change from monthly to quarterly. No M&A activity or strategic developments.
- Legato Merger Corp IV/Key Person Risk↓ [MEDIUM RISK]▼
CIO resignation with no successor named could delay or derail deal execution. Departure for 'personal reasons' but timing is concerning.
Opportunities (8)
- McKinley Acquisition Corp/Space-Eyes Merger↓ (OPPORTUNITY)◆
Pro-forma equity value of $638M for a defense-tech AI company with counter-drone technology. PIPE financing of up to $75M provides additional capital. Expected close Q4 2026. Investors can gain exposure to high-growth geospatial intelligence at SPAC pricing.
- CoreCivic/DHS Facility Sale↓ (OPPORTUNITY)◆
$734M sale generates $522.5M net proceeds while retaining operating contracts. Company has begun preliminary discussions about selling additional facilities. Potential for further value unlocking and debt reduction.
- Eton Pharmaceuticals/ASN-001 Licensing↓ (OPPORTUNITY)◆
Late-stage product with strong Phase II/III data (56% efficacy vs 15% placebo) targeting 20,000-30,000 annual patients. Patent protection through 2044. NDA submission expected 2H 2027 with potential 2028 launch. Low current valuation provides asymmetric upside.
- Palomino Laboratories/Vega Links Acquisition↓ (OPPORTUNITY)◆
Closed acquisition expanding addressable market 10x to $60B+ in AI interconnects. New CTO and CPO from industry bring expertise. Positioned for AI infrastructure spending boom.
- NCR Voyix Corp/Recurring Revenue Growth↓ (OPPORTUNITY)◆
Software and services revenue grew to $497M with recurring revenue of $435M. Adjusted EBITDA improved to $98M. Full-year guidance maintained at $2,188M-$2,303M. Potential turnaround play as hardware transition completes.
- Medalist Diversified REIT/Debt Reduction↓ (OPPORTUNITY)◆
Debt reduced 52.3% from $19.2M to $9.2M, equity increased 11.3% to $44.4M. Cleaner balance sheet positions company for new acquisitions at potentially distressed prices.
- BOA Acquisition Corp II/Infrastructure Focus↓ (OPPORTUNITY)◆
$125M SPAC targeting real estate and infrastructure in energy, telecom, and transportation. Sector-specific mandate could attract high-quality targets in growing infrastructure space.
- East West Ave Acquisition Corp/Fresh SPAC↓ (OPPORTUNITY)◆
$100M IPO provides dry powder for future M&A. No target identified yet, but early-stage SPACs often offer attractive risk/reward for investors who can wait for deal announcement.
Sector Themes (5)
- SPAC Activity Surge◆
5 of 14 filings involve SPACs (East West Ave IPO, BOA Acquisition Corp II IPO, McKinley merger, Charlton Aria extension, Inflection Point vote). Total SPAC capital raised/committed exceeds $363M, indicating renewed interest in blank-check vehicles despite regulatory scrutiny.
- Defense & Government Contracting Focus◆
CoreCivic's $734M DHS facility sale and McKinley's Space-Eyes merger (counter-drone tech) highlight growing investor interest in defense and government-related assets. Both transactions involve long-term government contracts or strategic government relationships.
- AI Infrastructure Buildout◆
Palomino Laboratories' acquisition of Vega Links (AI interconnects) and Eton Pharmaceuticals' licensing deal (though healthcare) reflect broader AI theme. Palomino's addressable market expansion to $60B+ underscores the massive opportunity in AI-enabling technologies.
- Portfolio Restructuring & Deleveraging◆
Medalist Diversified REIT's $76.6M in property dispositions and debt reduction (52.3%) and CoreCivic's asset sale for debt repayment show a trend of companies strengthening balance sheets through strategic asset sales. This could signal a shift toward capital efficiency.
- SPAC Distress Signals◆
Charlton Aria (second extension, no target), New America Acquisition I (director departures), and Inflection Point (shareholder approval without disclosure) indicate that many SPACs are struggling to find viable targets. This creates both risks and opportunities for disciplined investors.
Watch List (8)
-
Deadline extended to October 25, 2026. Must announce a merger target or face liquidation. Watch for any target announcement or further extensions.
-
Expected close Q4 2026. Monitor for shareholder vote, regulatory approvals, and PIPE financing details. S-4 filing will provide more deal specifics.
-
Preliminary discussions about selling more facilities to ICE. Any definitive agreement would be a significant catalyst. Watch for further 8-K filings.
-
Bioavailability bridging study and NDA submission expected 2H 2027. Monitor for clinical trial updates and FDA interactions. Patent litigation watch.
-
Q3 2026 earnings will show if revenue stabilization continues. Watch for any guidance revision from the $2,188M-$2,303M full-year outlook.
-
Monitor for initial revenue contributions from Vega Links and any new customer announcements. Integration execution will be key.
-
Watch for any definitive agreement announcement or further director departures. The lack of disclosure suggests a potential liquidation scenario.
-
IPO closed August 5, 2026. Monitor for target identification in real estate/infrastructure sectors. 24-month window to complete a deal.
Filing Analyses
(14)
05-08-2026
Eton Pharmaceuticals licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage product candidate for moderate infantile hemangiomas. Phase II/III data showed 56% (BID) and 42% (TID) elimination/near-elimination rates at week 24 vs. 15% for placebo. The company expects to submit an NDA in 2H 2027 with potential launch in 2028, targeting an estimated 20,000–30,000 annual patients. However, the product is still in development with no guaranteed approval, and the company faces risks from off-label competition and regulatory hurdles.
- · ASN-001 has patent protection through 2044 with an additional patent application pending.
- · Eton will run a bioavailability bridging study before NDA submission.
- · ASN-001 is expected to be prescribed by the same healthcare professionals as HEMANGEOL, leveraging existing commercial infrastructure.
- · The total U.S. infantile hemangioma market affects more than 100,000 infants annually.
- · HEMANGEOL is the standard of care for systemic therapy, representing 10,000–15,000 patients annually.
05-08-2026
The filing is an 8-K by New America Acquisition I Corp. (a SPAC) announcing the departure of directors and officers, a Regulation FD disclosure, and financial statements/exhibits related to a merger or acquisition. However, the filing does not disclose the specific merger/acquisition target, deal size, valuation, or strategic rationale. The only actionable information is the departure of certain officers and directors, which may indicate a de-SPAC transaction is in progress, but no quantitative financial data is provided.
- · The filing is an 8-K with Items 5.02, 7.01, and 9.01, but no specific financial statements or exhibits are described.
- · No target company, deal size, or valuation metrics are disclosed in the filing summary.
- · The departure of directors/officers is noted but names and effective dates are not provided.
05-08-2026
The filing is an 8-K submitted by Inflection Point Acquisition Corp. III (a SPAC) reporting the results of a shareholder vote on its proposed business combination. Shareholders approved the merger agreement and related proposals. However, the filing does not disclose the target company, deal size, valuation metrics, or any financial details. The transaction remains a blank-check merger with no quantitative data on premiums, exchange ratios, or synergies.
- · Shareholders voted to approve the business combination agreement and related proposals.
- · No target company, deal size, or financial terms are disclosed in this filing.
- · No information on shareholder redemptions, PIPE investment, or trust account balance.
05-08-2026
East West Ave Acquisition Corp. announced the pricing of its $100 million initial public offering of 10,000,000 units at $10.00 per unit, with the units expected to trade on Nasdaq under 'EWAVU' starting July 31, 2026. The offering is expected to close on August 3, 2026, subject to customary conditions, and the underwriters have a 45-day option to purchase up to 1,500,000 additional units. As a blank check company, it has not yet identified a target business, and there is no assurance the offering will be completed on the described terms or at all.
- · Each unit consists of one share of common stock and one right to receive one-fourth of one share of common stock upon consummation of an initial business combination.
- · Upon separate trading, common stock and rights are expected to be listed under 'EWAV' and 'EWAVR' respectively.
- · The registration statement on Form S-1 (File No. 333-295205) was declared effective by the SEC on July 13, 2026.
- · The company is a blank check company with no limitation on target industry or geographic region.
05-08-2026
NCR Voyix reported Q2 2026 revenue of $523M, down 21% YoY due to the Hardware Business Transition, but up 1% on a pro forma basis. Software and services revenue grew to $497M, recurring revenue rose to $435M, and Adjusted EBITDA increased to $98M. However, net loss from continuing operations was $1M, and diluted EPS from continuing operations remained negative at $(0.03). The company maintained its full-year 2026 outlook with revenue expected between $2,188M and $2,303M.
- · Net loss from continuing operations was $1M in Q2 2026 vs. $0 in Q2 2025.
- · Diluted EPS from continuing operations remained flat at $(0.03) YoY.
- · Non-GAAP diluted EPS was flat at $0.17 YoY.
- · Full-year 2026 revenue outlook (GAAP) implies a decline of 13% to 18% YoY.
- · Full-year 2026 pro forma revenue outlook ranges from -2% to +3% YoY.
- · Adjusted Free Cash Flow (unrestricted, before restructuring) outlook for 2026 is $190M to $220M, representing 40% to 62% growth.
- · The company repurchased $11M of common stock in Q2 2026.
- · In July 2026, NCR Voyix signed a contract with Pizza Ranch for Aloha Next and Voyix Pay at over 200 restaurants.
- · In May 2026, the company announced a partnership with Voyager for fleet card acceptance via Voyix Connect.
05-08-2026
Medalist Diversified REIT completed seven property dispositions and a deconsolidation between October 2025 and July 2026, generating total sales proceeds of approximately $76.6 million. The company used a significant portion of the proceeds to repay debt, including $7.0 million on the Wells Fargo facility and full repayment of several mortgage loans. While the dispositions generated substantial gains, the pro forma results show a sharp decline in revenue and a shift to a net operating loss, reflecting the reduced income-generating asset base.
- · The company deconsolidated XXV DST 1 (Tesla Pensacola Property) after selling 84.72% of Class 1 beneficial interests, receiving approximately $6.78M in net cash proceeds.
- · Pro forma total assets declined 19.4% from $68.9M to $55.6M, while total equity increased 11.3% from $39.9M to $44.4M.
- · Pro forma mortgages payable were reduced by 52.3% from $19.2M to $9.2M.
- · Pro forma net loss from operations for Q1 2026 was approximately $1.27M, compared to historical net income of $11.84M (which included large gains on disposals).
- · The company retained a 15.28% beneficial ownership interest in XXV DST 1, recorded as an equity investment of $1.31M on the pro forma balance sheet.
05-08-2026
Charlton Aria Acquisition Corp. (Nasdaq: CHAR, CHARU, CHARR) announced that its sponsor deposited $850,000 into the trust account to extend the deadline for completing an initial business combination by three months, from July 25, 2026 to October 25, 2026. This is the second of two permitted three-month extensions, bringing total sponsor deposits to $1,700,000. The company has not yet identified a target business and faces the risk of not completing a combination by the extended deadline.
- · The company had until April 25, 2026 (18 months from IPO) to complete a business combination, but can extend twice by three months each with sponsor deposits.
- · First extension deposit of $850,000 was made on April 24, 2026, extending the deadline to July 25, 2026.
- · The company is a blank check company with no target business identified and no industry or geographic restrictions.
- · No assurance is given that a business combination will be completed by October 25, 2026, or at all.
05-08-2026
Palomino Laboratories completed the acquisition of Vega Links Inc., transforming into a comprehensive AI interconnect company and expanding its estimated addressable market by approximately 10x to over $60 billion. The company appointed Karthik Gopalakrishnan as CTO and Rajesh Radhamohan as CPO, and added Sudeep Bhoja and Dr. Gopal Raghavan to its Strategic Advisory Board. While the acquisition is expected to accelerate growth, the company faces risks typical of forward-looking statements and integration challenges.
- · Vega Links acquisition closed on schedule after definitive agreements and satisfaction of all closing conditions.
- · Palomino's product focus includes AI interconnect solutions in the 0-to-50 meters range.
- · The company believes future AI clusters will rely on heterogeneous interconnect technologies, with copper remaining important for short-reach applications and optical technologies (MicroVCSEL, MicroLED) playing an increasing role.
- · Sources cited: LightCounting Dec 2025 AEC/ACC report and Apr 2026 Switch ASIC & Optics report.
05-08-2026
McKinley Acquisition Corp. (MKLY) announced a definitive business combination agreement with Space-Eyes, Inc., a provider of AI-driven geospatial intelligence and counter-drone technology. The transaction implies a pro-forma equity valuation of $638 million for Space-Eyes, with up to $75 million in PIPE financing sourced to augment $176.7 million of trust capital. The deal is expected to close in Q4 2026, subject to shareholder and regulatory approvals, and Eric Trump has been announced as an investor and strategic adviser.
- · The PIPE includes $5 million in senior secured convertible notes at initial closing upon S-4 filing, with proceeds held in a control account.
- · Additional $70 million in senior secured convertible notes and warrants may be issued at subsequent closings, subject to conditions.
- · At subsequent closing, Space-Eyes must issue shares equal to 9.9% of McKinley's outstanding common stock post-merger to PIPE buyers.
- · Notes bear interest at 10% per annum and mature in 2031; warrants have an exercise price of $12.00 per share.
- · The conversion price of notes is the lower of $12.00 or 120% of the last reported sale price post-business combination.
- · The securities issued under the SPA are secured by a first-priority security interest in substantially all assets of Space-Eyes and its subsidiaries.
- · Upon business combination, Space-Eyes notes and warrants will be exchanged for McKinley notes and warrants on materially identical terms.
- · The combined company will be named Space-Eyes, Inc. and is expected to trade on Nasdaq under ticker CUAS.
- · Eric Trump is announced as an investor and strategic adviser.
05-08-2026
CoreCivic completed the sale of two detention facilities (Prairie Correctional Facility and Midwest Regional Reception Center) to the U.S. Department of Homeland Security for an aggregate gross sales price of $734.0 million, generating net proceeds of approximately $522.5 million after taxes and transaction costs. The company will continue to operate both facilities under existing ICE management contracts, which expire in August 2031 and September 2027, respectively. However, the company cautioned that ICE retains the right to terminate the contracts for non-appropriation or convenience, and preliminary discussions about selling additional facilities to ICE may not result in any further transactions.
- · The management contracts for Prairie Correctional Facility and Midwest Regional Reception Center expire in August 2031 and September 2027, respectively.
- · ICE has the ability to terminate the management contracts for non-appropriation of funds or for convenience.
- · The company has begun preliminary discussions with ICE about the potential acquisition of additional detention facilities, but no assurance of any additional sales.
- · CoreCivic's portfolio after the sale includes 61 owned/leased facilities (67,000 beds) and 8 managed-only facilities (13,000 beds).
05-08-2026
AmperCap Acquisition Company (APMC) amended its Administrative Services Agreement with sponsor AmperSPAC LLC on July 31, 2026, changing the payment schedule for the monthly $5,000 Services Fee from monthly to quarterly payments in advance. The amendment is effective July 1, 2026, and includes a provision for refund of any unaccrued portion if the agreement terminates mid-quarter. This is a routine administrative change with no financial impact beyond cash flow timing.
- · The amendment changes payment timing from monthly to quarterly in advance, effective July 1, 2026.
- · Any unaccrued portion of the Services Fee paid for a month must be refunded within five business days of the Termination Date.
- · The Original Agreement was entered into on June 2, 2026, and disclosed on a Form 8-K dated June 5, 2026.
05-08-2026
Legato Merger Corp. IV (LEGO) announced the resignation of Chief Investment Officer Ehsan Ehsani effective July 31, 2026. The departure is for personal reasons and not due to any disagreement with the company. No replacement or interim appointment has been disclosed.
- · The resignation was effective July 31, 2026.
- · The filing was made on August 5, 2026.
- · No successor or interim Chief Investment Officer has been named.
05-08-2026
BOA Acquisition Corp. II priced its $125 million initial public offering of 12,500,000 units at $10.00 per unit, with the units expected to trade on Nasdaq under the ticker "THEOU" starting August 4, 2026. The SPAC intends to focus its search for a business combination on direct investments in real estate and infrastructure assets, particularly in energy, telecommunications, and transportation sectors. The offering is expected to close on August 5, 2026, and the underwriters have a 45-day option to purchase up to 1,875,000 additional units to cover over-allotments.
- · The SPAC was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
- · The company intends to focus its search on opportunities involving direct investments in real estate and infrastructure assets, particularly within the energy, telecommunications and transportation sectors.
- · The registration statement on Form S-1 (File No. 333-290732) was declared effective by the SEC on August 3, 2026.
- · The underwriters have a 45-day option to purchase up to 1,875,000 additional units at the IPO price to cover over-allotments.
05-08-2026
The filing is a merger/acquisition announcement by Catalyst Acquisition Corp. dated August 5, 2026. However, the filing contains no specific details on the deal structure, parties involved, valuation, or financial terms. All key quantitative data is not disclosed, making it impossible to assess the strategic rationale, shareholder impact, or market implications. The analysis is severely limited by the lack of substantive information in the filing.
Get daily alerts with 12 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 14 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Merger & Acquisition SEC Filings
🇺🇸 More from United States
View all →August 06, 2026
US Pre-Market SEC Filings Roundup — August 06, 2026
US Pre-Market SEC Filings Roundup
August 06, 2026
USA Corporate Events Calendar — August 06, 2026
USA Corporate Events Calendar
August 06, 2026
USA Earnings Calls Schedule — August 06, 2026
USA Earnings Calls Schedule
August 05, 2026
US Pre-Market SEC Filings Roundup — August 05, 2026
US Pre-Market SEC Filings Roundup